ClinicalTrials.gg
CompletedNCT05152173Updated Mar 27, 2026Results posted

Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis

A Phase 2 interventional study of EN3835 and Placebo in Plantar Fibromatosis, sponsored by Endo USA Inc., a Keenova Therapeutics Company. Completed at 43 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Endo USA Inc., a Keenova Therapeutics Company (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of up to 2 treatments of EN3835 vs placebo in participants with plantar fibromatosis.

02

Conditions studied

  • Plantar Fibromatosis
03

In context

Lead sponsor

Endo USA Inc., a Keenova Therapeutics Company is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a diagnosis of plantar fibromatosis AND have at least 1 measurable, hard or firm, palpable fibrous nodule on clinical examination.
  2. Has no significant medical history or examination findings related to the participant's plantar nodule(s), which in the investigator's opinion, would make the participant unsuitable for study intervention administration.
  3. Agree not to use opioids during the study period and has not used opioids 2 weeks before the Screening Visit.
  4. Agree to not initiate or change use of orthotics or inserts designed to relieve symptoms of plantar fibromatosis during the study period.
  5. If female, be of non- (history of hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or with no history of menstrual flow in the 12 months prior to the Screening Visit); or, if of childbearing potential, be non-pregnant, non-lactating and agree to use effective when with a male partner for the duration of the study and for 28 days after any active treatment period.
  6. Willing and able to comply with all protocol required visits and assessments.
  7. Be adequately informed and understand the nature and risks of the study and be able to provide consent.

Exclusion criteria

Exclusion Criteria:

  1. Has the presence of non-plantar fibromatosis-related nodules on the foot/feet (eg, neurofibroma, rhabdomyosarcoma, liposarcoma, neurilemmomas, rheumatoid nodules, desmoid tumors, or malignant soft tissue lesions of the foot or ankle).
  2. Has any musculoskeletal, neuromuscular, neurosensory, other neurological or related disorder that affects the participant's use of his or her feet and/or would impair his/her completion of study assessments as determined by the investigator.
  3. Has a known allergy to collagenase or any other of EN3835.
  4. Has a known coagulation disorder or is taking any medications that would increase the risk of bleeding (except \<150mg of aspirin daily), 7 days prior to first injection and for the duration of the study.
  5. Has concurrent diseases that might interfere with the conduct of the study, confound the interpretation of the study results or endanger the participant's well-being. If there is a history of such disease and the condition has been stable for greater than one year and is judged by the investigator not to interfere, the participant may be included, with the documented approval of the Medical Monitor.
  6. Is from a vulnerable population, as defined by the US Code of Federal Regulations (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations, including but not limited to, employees (temporary, part-time, full-time, etc) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the IRB/IEC.
  7. Has any other condition(s) that, in the investigator's opinion, might indicate the participants to be unsuitable for the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    EN3835 Group

    Participant will receive a maximum dose of up to 1.8mg of EN3835 injection

    Biological: EN3835

  • Placebo comparator
    Placebo Group

    Participant will receive a matched Placebo injection

    Other: Placebo

Interventions

  • BiologicalEN3835

    Participant will receive a maximum dose of up to1.8mg of EN3835 injection

  • OtherPlacebo

    Participant will receive a matched Placebo injection

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 57 in the Foot Function Index (FFI) Pain Subscale Score

    FFI pain subscale consisted of 9 items which were scored on a scale of 0 ("None") to 4 ("Extreme") with a total score ranging from 0 to 36. Lower scores indicated better foot function, while higher scores reflected greater impairment.

    Time frame: Baseline (Day 1), Day 57

Secondary outcomes

  1. Change From Baseline to Day 57 in the FFI Total Combined (Pain and Difficulty) Score

    The FFI pain subscale consisted of 9 items which were scored on a scale of 0 ("None") to 4 ("Extreme") with a total score ranging from 0 to 36. The FFI difficulty subscale consisted of 9 items which were scored on a scale of 0 ("No difficulty") to 4 ("A lot of difficulty") with a total score ranging from 0 to 36. The Total Combined score of pain and difficulty comprised scores of answered items in each subscale with a maximum total score range of 0 to 72. Lower scores indicated better foot function, while higher scores reflected greater impairment.

    Time frame: Baseline (Day 1), Day 57

  2. Percentage of Participants With a Response of "Minimal Improvement", "Much Improvement" or "Very Much Improvement" (Responders) in the Clinician Global Impression of Change Scale

    The responder (by foot/feet) was defined as a participant with a response of "Minimal Improvement", "Much Improvement" or "Very Much Improvement" in the CGIC Scale. All participants who withdrew early from the study were considered as non-responders. If participant was treated for both feet, then the assessment could be combined at participant level using worst case approach, if one foot response was recorded as 'Minimal Improvement' and 'Very Much Improvement' in another foot, then response was considered as 'Minimal Improvement'.

    Time frame: Day 57

  3. Change From Baseline to Day 57 in the Nodular Hardness of the Treated Nodules by Durometer Measurement

    A durometer was used to measure the hardness of treated nodules, on a scale ranging from 0 to 100. Higher scores indicated a greater hardness.

    Time frame: Baseline (Day 1), Day 57

07

Results

Posted Mar 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneEN3835 GroupPlacebo Group
Started8888
Intent to treat set8888
Received at least 1 dose of study drug8787
Completed8383
Not completed55
Withdrew: Lost to follow-up31
Withdrew: Sponsor decision01
Withdrew: Other23

Outcome measures

PrimaryChange From Baseline to Day 57 in the Foot Function Index (FFI) Pain Subscale Score

FFI pain subscale consisted of 9 items which were scored on a scale of 0 ("None") to 4 ("Extreme") with a total score ranging from 0 to 36. Lower scores indicated better foot function, while higher scores reflected greater impairment.

Time frame:
Baseline (Day 1), Day 57
Reported as:
Least squares mean · score on a scale
Change From Baseline to Day 57 in the Foot Function Index (FFI) Pain Subscale Score
score on a scaleEN3835 GroupPlacebo Group
Change From Baseline to Day 57 in the Foot Function Index (FFI) Pain Subscale Score-9.844 ± 0.91-8.417 ± 0.89
Statistical analysis
  • EN3835 Group vs Placebo Group · ANCOVA · p = 0.274 (Significance=0.05) · Ls mean difference: -1.427 · 95% CI -3.985 to 1.131Treatment effect and 95% CI for comparing EN3835 with placebo was estimated using ANCOVA with treatment group as fixed effect, FFI Total Pain Subscale Score at baseline, maximum of nodule length and total number of treated nodules as covariates.
SecondaryChange From Baseline to Day 57 in the FFI Total Combined (Pain and Difficulty) Score

The FFI pain subscale consisted of 9 items which were scored on a scale of 0 ("None") to 4 ("Extreme") with a total score ranging from 0 to 36. The FFI difficulty subscale consisted of 9 items which were scored on a scale of 0 ("No difficulty") to 4 ("A lot of difficulty") with a total score ranging from 0 to 36. The Total Combined score of pain and difficulty comprised scores of answered items in each subscale with a maximum total score range of 0 to 72. Lower scores indicated better foot function, while higher scores reflected greater impairment.

Time frame:
Baseline (Day 1), Day 57
Reported as:
Least squares mean · score on a scale
Change From Baseline to Day 57 in the FFI Total Combined (Pain and Difficulty) Score
score on a scaleEN3835 GroupPlacebo Group
Change From Baseline to Day 57 in the FFI Total Combined (Pain and Difficulty) Score-19.145 ± 1.893-16.530 ± 1.858
SecondaryPercentage of Participants With a Response of "Minimal Improvement", "Much Improvement" or "Very Much Improvement" (Responders) in the Clinician Global Impression of Change Scale

The responder (by foot/feet) was defined as a participant with a response of "Minimal Improvement", "Much Improvement" or "Very Much Improvement" in the CGIC Scale. All participants who withdrew early from the study were considered as non-responders. If participant was treated for both feet, then the assessment could be combined at participant level using worst case approach, if one foot response was recorded as 'Minimal Improvement' and 'Very Much Improvement' in another foot, then response was considered as 'Minimal Improvement'.

Time frame:
Day 57
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of "Minimal Improvement", "Much Improvement" or "Very Much Improvement" (Responders) in the Clinician Global Impression of Change Scale
Percentage of participantsEN3835 GroupPlacebo Group
Percentage of Participants With a Response of "Minimal Improvement", "Much Improvement" or "Very Much Improvement" (Responders) in the Clinician Global Impression of Change Scale61 (59.0 to 78.0)48 (44.2 to 64.5)
SecondaryChange From Baseline to Day 57 in the Nodular Hardness of the Treated Nodules by Durometer Measurement

A durometer was used to measure the hardness of treated nodules, on a scale ranging from 0 to 100. Higher scores indicated a greater hardness.

Time frame:
Baseline (Day 1), Day 57
Reported as:
Least squares mean · score on a scale
Change From Baseline to Day 57 in the Nodular Hardness of the Treated Nodules by Durometer Measurement
score on a scaleEN3835 GroupPlacebo Group
Change From Baseline to Day 57 in the Nodular Hardness of the Treated Nodules by Durometer Measurement-13.537 ± 1.76-7.660 ± 1.75

Adverse events

Collected over Day 1 to Day 57. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EN3835 Group0/88 (0%)0/87 (0%)58/87 (66.7%)
Placebo Group0/88 (0%)2/87 (2.3%)35/87 (40.2%)
Most frequent serious events
Most frequent serious events
EventEN3835 GroupPlacebo Group
Colitis ulcerativeGastrointestinal disorders0/871/87
Tendon injuryInjury, poisoning and procedural complications0/871/87
Most frequent other events
Showing 10 of 69
Most frequent other events
EventEN3835 GroupPlacebo Group
Injection site painGeneral disorders39/879/87
Injection site bruisingGeneral disorders37/872/87
Injection site swellingGeneral disorders25/873/87
NoduleGeneral disorders3/875/87
Injection site pruritisGeneral disorders5/870/87
Injection site oedemaGeneral disorders4/870/87
Tendon injuryInjury, poisoning and procedural complications3/870/87
ArthralgiaMusculoskeletal and connective tissue disorders1/873/87
COVID-19Infections and infestations3/870/87
Injection site discomfortGeneral disorders2/870/87

Baseline characteristics

The Intent to treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)EN3835 GroupPlacebo GroupTotal
Mean54.7 ± 10.9356.3 ± 10.5855.5 ± 10.75
Sex: Female, Male
Sex: Female, Male(Participants)EN3835 GroupPlacebo GroupTotal
Female5861119
Male302757
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EN3835 GroupPlacebo GroupTotal
Hispanic or Latino13922
Not Hispanic or Latino7477151
Unknown or Not Reported123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EN3835 GroupPlacebo GroupTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander011
Black or African American161733
White7169140
More than one race101
Unknown or Not Reported011
Foot Function Index (FFI) Total Pain Subscale Score
Foot Function Index (FFI) Total Pain Subscale Score(score on a scale)EN3835 GroupPlacebo GroupTotal
Mean25.30 ± 5.19924.84 ± 5.40125.07 ± 5.291
08

Study locations

43 sites
  • Endo Clinical Trial Site #29
    Mesa, Arizona 85206, United States
  • Endo Clinical Trial Site #42
    Tucson, Arizona 85712, United States
  • Endo Clinical Trial Site #15
    Bakersfield, California 93311, United States
  • Endo Clinical Trial Site #41
    Encinitas, California 92024, United States
  • Endo Clinical Trial Site #9
    Fresno, California 93710, United States
  • Endo Clinical Trial Site #27
    La Mesa, California 91942, United States
  • Endo Clinical Trial Site #30
    Los Angeles, California 90010, United States
  • Endo Clinical Trial Site #12
    Tarzana, California 91356, United States
  • Endo Clinical Trial Site #36
    Torrance, California 90502, United States
  • Endo Clinical Trial Site #22
    Vista, California 92083, United States
  • Endo Clinical Trial Site #13
    Whittier, California 90603, United States
  • Endo Clinical Trial Site #16
    Atlantis, Florida 33462, United States
  • Endo Clinical Trial Site #43
    Jacksonville, Florida 32209, United States
  • Endo Clinical Trial Site #40
    Miami, Florida 33176, United States
  • Endo Clinical Trial Site #10
    Pinellas Park, Florida 33782, United States
  • Endo Clinical Trial Site #3
    South Miami, Florida 33143, United States
  • Endo Clinical Trial Site #14
    Sweetwater, Florida 33172, United States
  • Endo Clinical Trial Site #38
    Lawrenceville, Georgia 30043, United States
  • Endo Clinical Trial Site #31
    Meridian, Idaho 83642, United States
  • Endo Clinical Trial Site #32
    Decatur, Illinois 62521, United States
  • Endo Clinical Trial Site #19
    O'Fallon, Illinois 62269, United States
  • Endo Clinical Trial Site #33
    Springfield, Illinois 62704, United States
  • Endo Clinical Trial Site #23
    Pasadena, Maryland 21122, United States
  • Endo Clinical Trial Site #28
    Jefferson City, Missouri 65109, United States
  • Endo Clinical Trial Site #20
    Las Vegas, Nevada 89119, United States
  • Endo Clinical Trial Site #34
    Oklahoma City, Oklahoma 73109, United States
  • Endo Clinical Trial Site #4
    York, Pennsylvania 17402, United States
  • Endo Clinical Trial Site #35
    Arlington, Texas 76015, United States
  • Endo Clinical Trial Site #5
    Bedford, Texas 76021, United States
  • Endo Clinical Trial Site #24
    Cedar Park, Texas 78613, United States
  • Endo Clinical Trial Site #17
    Dallas, Texas 75208, United States
  • Endo Clinical Trial Site #2
    Dallas, Texas 75251, United States
  • Endo Clinical Trial Site #7
    Fort Worth, Texas 76104, United States
  • Endo Clinical Trial Site #39
    Georgetown, Texas 78628, United States
  • Endo Clinical Trial Site #25
    Houston, Texas 77027, United States
  • Endo Clinical Trial Site #8
    Houston, Texas 77095, United States
  • Endo Clinical Trial Site #1
    McAllen, Texas 78501, United States
  • Endo Clinical Trial Site #21
    San Antonio, Texas 78211, United States
  • Endo Clinical Trial Site #6
    San Antonio, Texas 78229, United States
  • Endo Clinical Trial Site #18
    Salt Lake City, Utah 84107, United States
  • Endo Clinical Trial Site #26
    Lynchburg, Virginia 24501, United States
  • Endo Clinical Trial Site #37
    Midlothian, Virginia 23114, United States
  • Endo Clinical Trial Site #11
    Suffolk, Virginia 23434, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jan 2023, 13 months.

Results were first posted in Mar 2026, 3 years 2 months after primary completion. A results delay was requested in Jan 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2021
First posted
Dec 9, 2021
StartActual
Nov 29, 2021
Primary completionActual
Jan 10, 2023
CompletionActual
Jan 10, 2023
Results delay requested
Jan 4, 2024
Results first posted
Mar 27, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05152173
Responsible party
Sponsor
First posted
Dec 9, 2021
Start date
Nov 29, 2021
Primary completion
Jan 10, 2023
Completion
Jan 10, 2023
Results posted
Mar 27, 2026
Last update
Mar 27, 2026

Study contacts

Luis Ortega, MD
study director · Endo USA Inc., a Keenova Therapeutics Company

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion